Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8321386 | 0.86 | BRD4 (0.44) | BRD4PTPN11HTR6CDK8ELANE | |
| SCHEMBL1487554 | 0.83 | BRD4 (0.42) | BRD4PTPN11HTR6CDK8CYP2C19 | |
| SCHEMBL13745805 | 0.83 | BRD4 (0.41) | BRD4PTPN11HTR6CDK8PDPK1 | |
| SCHEMBL13745808 | 0.82 | BRD4 (0.40) | BRD4PTPN11HTR6CDK8ELANE | |
| SCHEMBL1487581 | 0.82 | BRD4 (0.43) | BRD4PTPN11HTR6CDK8CYP2C19 | |
| SCHEMBL13746023 | 0.82 | BRD4 (0.45) | BRD4PTPN11HTR6CDK8PDPK1 | |
| SCHEMBL2753498 | 0.81 | PDPK1 (0.49) | BRD4PTPN11HTR6CDK8PDPK1 | |
| SCHEMBL1487552 | 0.81 | PTPN11 (0.47) | BRD4PTPN11HTR6CDK8PDPK1 | |
| SCHEMBL1487551 | 0.81 | BRD4 (0.42) | BRD4PTPN11HTR6CDK8PDPK1 | |
| SCHEMBL1487601 | 0.80 | BRD4 (0.41) | BRD4PTPN11HTR6CDK8CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | BRD4 1339/4885PTPN11 1694/4885HTR6 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.